6-K

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM6-K

REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDERTHE SECURITIES EXCHANGE ACT OF 1934

For the month of March, 2021

CommissionFile Number: 001-36582

AurisMedical Holding Ltd.

(Exactname of registrant as specified in its charter)

ClarendonHouse, 2 Church Street

HamiltonHM 11, Bermuda

(Addressof principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒        Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ☐        No ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ☐        No ☒

Noticeof Warrant Exercise and Loan Conversion

Auris Medical Holding Ltd. (NASDAQ: EARS, the “Company”) today announced that on March 9, 2021 one investor in the May 2019 financing of common shares and warrants (the “May 2019 Offering”) exercised warrants for 897,435 common shares at the exercise price of CHF 4.34 per share, for net proceeds of approximately USD 4.2 million. Together with the previously announced exercises by other investors in the May 2019 Offering in December 2020 for 1,263,845 common shares, all warrants issued through the May 2019 Offering have been exercised by now.

In addition, the Company announced that FiveT Capital Holding Ltd. (“FiveT”) converted on March 4, 2021 the remaining principal amount and accrued interest of a convertible loan to its affiliate Altamira Medica Ltd. into common shares of Medical Holding Ltd. at the maximum conversion price of USD 1.35 per share. The loan of CHF 1.5 m had been disbursed on September 8, 2021 with a duration of 18 months and carried an interest rate of 8% p.a.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 12, 2021

2